NCT00511706View on ClinicalTrials.gov

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

PHASE2CompletedINTERVENTIONAL
Enrollment

243

Participants

Timeline

Start Date

November 1, 2007

Primary Completion Date

March 1, 2009

Study Completion Date

March 1, 2009

Conditions
Choroidal NeovascularizationAge-Related Maculopathy
Interventions
DRUG

dexamethasone

Intravitreal injection of dexamethasone 700 µg at Day 1.

BIOLOGICAL

ranibizumab

Ranibizumab 500 µg at day -30 and Day 7-14.

OTHER

sham

Sham needle-less injection administered in the study eye at Day 1.

Trial Locations (9)

Unknown

Boynton Beach

Parramatta

Paris

Tel Aviv

Milan

Auckland

Coimbra

Seoul

Southampton

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY